Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

A Nice Buying Opportunity In Tonix Pharma

On March 27, 2014, an article was posted to Seeking Alpha calling Tonix Pharmaceuticals (NASDAQ:TNXP), "extremely over-priced" and the company's lead pipeline candidate, TNX-102SL, "completely unneeded." The article was authored by Bioassociate Consulting, an Israeli-based consulting company with claimed expertise in the life science arena, specifically with respect to providing research and analysis services to international life science companies and investment entities (investment banks, private and institutional investors). In connection with the article, the authors have assumed a short position in the stock.

The authors make three key assertions as to why Tonix is over-valued and the drug is unneeded. We summarize their position:

  1. Tonix's reformulated cyclobenzaprine does not provide any benefits over generic cyclobenzaprine;
  2. If approved, Tonix
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details